Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

extranodal nasal NK/T cell lymphoma News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A single-center study in Vietnam evaluates real-world outcomes of frontline multimodal treatment strategies for localized extranodal NK/T-cell lymphoma, nasal type. The findings contribute to understanding treatment efficacy in this rare lymphoma subtype.

A case report highlights the occurrence of synchronous rectal cancer and extranodal NK/T-cell lymphoma, nasal type. This unique presentation may provide insights into the interplay between these two malignancies.

New research identifies DNA methylation signatures that differentiate extranodal NK/T-cell lymphoma from EBV-positive nodal T/NK-cell lymphoma. This discovery may help in identifying prognostic subgroups, enhancing patient stratification and treatment approaches.

The phase II NCCH1903/ATTACK trial evaluates atezolizumab for patients with relapsed or refractory extranodal NK/T-cell lymphoma. This study contributes to the understanding of immunotherapy options for this rare lymphoma subtype.

A recent publication discusses the differential diagnosis of facial lesions, specifically focusing on extranodal NK/T-cell lymphoma in the nasal region. This research contributes to the understanding of rare lymphomas and their clinical presentation.

A multicenter cohort study of 755 patients reveals outcomes with first-line PD1 inhibitors in extranodal NK/T-cell lymphoma. This analysis provides valuable insights into treatment efficacy and patient responses.

Not rare diseases news,news about your rare disease.